ALT240927P7500
- 0.70
- +0.19+37.25%
Altimmune Newsroom
Institutional Investors Control 60% of Altimmune, Inc. (NASDAQ:ALT) and Were Rewarded Last Week After Stock Increased 11%
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
Altimmune Spikes After Presenting Data for Obesity Drug
Express News | Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial
Express News | Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60TH Annual Meeting of the European Association for the Study of Diabetes
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Decoding 4 Analyst Evaluations For Altimmune
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Express News | B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Altimmune Analyst Ratings
Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
Evercore ISI Remains a Buy on Altimmune (ALT)
Altimmune, Inc. (ALT): A Good GLP-1 and Weight Loss Stock to Buy Now?
Buy Rating Affirmed for Altimmune as Pemvidutide Poised to Lead NASH Treatment Market